Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 | 42 | ModernaTX, Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07728942 | SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05608148 | Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors | recruiting | Phase 1 | 61 | Kyushu UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752953 | Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors(ZSNeo-DC-RWS) | recruiting | N/A | 100 | ZSky Biotech IncINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753499 | Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer | recruiting | N/A | 120 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01050504 | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer | recruiting | — | 1,500 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 63 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 499 | Arvinas Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 220 | Strand Therapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04967833 | A Study of GC101 TIL in Advanced Solid Tumors (TR) | recruiting | Early Phase 1 | 20 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05087745 | A Clinical Study on TIL for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06089408 | Weighted Blanket Use to Reduce Anxiety in Oncology Patients | recruiting | N/A | 114 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07256756 | A Study of GC203 TIL in Advanced Solid Tumors (NF) | recruiting | Phase 1 | 8 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05238792 | Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors(ATTACK) | recruiting | Phase 1 | 24 | Children's National Research InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05471856 | A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 66 | Boehringer IngelheimINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06832982 | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 | recruiting | Phase 1 | 66 | Shanghai Pushi Medical Science Co. LtdINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06880861 | Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers(IMPACT) | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05687110 | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07601243 | Study of GS-2426 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Gilead SciencesINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07680582 | An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | recruiting | Early Phase 1 | 60 | Ruijin HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741435 | Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia(METHYLSCAPE-CO) | recruiting | — | 3,250 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 681 | Astellas Pharma IncINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07737509 | Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis(MC2) | recruiting | — | 5,000 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01620372 | French Childhood Cancer Survivor Study(FCCSS) | recruiting | — | 18,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05039632 | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05245136 | Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.(ALPS) | recruiting | — | 3,000 | University Hospital AugsburgOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07669415 | A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 108 | LaNova Medicines LimitedINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02029001 | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment(MOST plus) | recruiting | Phase 2 | 900 | Centre Leon BerardOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05411523 | Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy | recruiting | — | 20 | Mayo ClinicOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06206863 | Community-Based Physical Activity Intervention for Underserved Cancer Survivors | recruiting | N/A | 200 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06565260 | Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06569316 | Genetic Testing for the Prevention of Cancer in American Indian Communities (JUNIPER Trial) | recruiting | N/A | 300 | Mayo ClinicOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07374419 | Atamparib in Patients With Advanced Solid Tumors(PARP7) | recruiting | Phase 1 / Phase 2 | 178 | Nerviano Medical Sciences (Shanghai) Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 | 209 | Chugai PharmaceuticalINDUSTRY | 2 | Jul 28, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 3 | Jul 28, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials